24/7 Market News Snapshot 04 June, 2025 – GlucoTrack, Inc. Common Stock (NASDAQ:GCTK)

June 4, 2025

DENVER, Colo., 04 June, 2025 (www.247marketnews.com) – (NASDAQ:GCTK) are discussed in this article.
GlucoTrack, Inc. (GCTK) has recently demonstrated a significant positive movement in its stock performance, opening at $0.145 and currently trading at $0.153, which marks a commendable 6.99% increase. With a trading volume of 6.63 million shares, the heightened investor interest suggests potential market volatility. The previous closing at $0.143 indicates a bullish trend as the stock surpasses key resistance levels. Market analysts advise investors to closely monitor technical patterns and overall market sentiment, as sustained interest could result in further upward movement or volatility in the stock price.

Concurrently, GlucoTrack, Inc. is poised to make substantial contributions to diabetes management through its groundbreaking continuous blood glucose monitoring technology. The company is set to present its first-in-human trial data at the upcoming American Diabetes Association’s 85th Scientific Sessions, taking place from June 20 to 23, 2025. This notable event will include a live presentation by Chief Scientific Officer Mark Tapsak, titled “Re-Imagining the Future of Continuous Glucose Monitoring with CBGM.” This session promises to reveal how GlucoTrack’s innovative implantable Continuous Blood Glucose Monitoring (CBGM) system can provide patients with real-time data directly from the bloodstream, thereby eliminating the need for on-body wearables.

Additionally, a poster summarizing the early findings from the feasibility study of the CBGM system will be presented on June 22, enabling detailed discussions on the system’s safety and performance metrics derived from the clinical trials, which hold the potential to transform diabetes care standards. Paul V. Goode, PhD, President and CEO of GlucoTrack, described the significance of participating in the ADA’s conference as a major milestone, underlining the company’s commitment to revolutionizing diabetes management with its innovative technology while minimizing daily disruptions for patients. Following the conference, comprehensive details from the poster presentation will be accessible on GlucoTrack’s website, ensuring broad dissemination of this pioneering research.

Related news for (GCTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.